ENPAC: phase II trial with safety lead of enzalutamide in combination with paclitaxel and carboplatin for advanced or recurrent endometrioid endometrial adenocarcinoma
Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Robert L. Coleman(Texas Oncology), Gordon B. Mills(The University of Texas MD Anderson Cancer Center), Ying Yuan(The University of Texas MD Anderson Cancer Center), Aaron Shafer(The University of Texas MD Anderson Cancer Center), Lauren Cobb(The University of Texas MD Anderson Cancer Center), Jolyn Taylor, Pamela T. Soliman(The University of Texas MD Anderson Cancer Center), Sara Hull(The University of Texas MD Anderson Cancer Center), Tina Alvarado(The University of Texas MD Anderson Cancer Center), Pedro T. Ramírez(Houston Methodist), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Michael Frumovitz(The University of Texas MD Anderson Cancer Center), Larissa A. Meyer, Nicole D. Fleming(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center)
Cited by 6
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k